Magnesium deficiency

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, February 28, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, SRPT, Hart–Scott–Rodino Antitrust Improvements Act, Investment, Interest, Sarepta Therapeutics, Part, Sale, University, Trial of the century, Ageing, BLA, GAAP, Therapy, BioMarin Pharmaceutical, Income tax, PMR, Depreciation, Magnesium deficiency, Nationwide Children's Hospital, Hospital, Safety, Patent, Clinical trial, Biologics license application, Mutation, Priority review, Acquisition, PIN, Dystrophin, FDA, Food, DMD, Duchenne muscular dystrophy, U.S. FDA, Agency, Patient, PRV, PMO, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.
  • Beginning in the fourth quarter of 2023, amortization of in-licensed rights (formerly included within depreciation and amortization expense) and income tax (benefit) expense are no longer excluded from the non-GAAP results.
  • Non-GAAP financial results for the fourth quarter and full-year 2022 have been updated to reflect this change for comparability.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
Tuesday, February 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Retrieved on: 
Monday, January 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Ageing, Patient, Therapy, Magnesium, Part, SRPT, Hypokalemia, Sarepta Therapeutics, DdPCR, Magnesium deficiency, PIN, Dystrophin, Catholic higher education, Duchenne muscular dystrophy, Interest, Vaccine

SRP-5051 is a next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Key Points: 
  • SRP-5051 is a next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
  • Consistent dystrophin expression was seen in ambulatory (4.76%, n=11) and non-ambulatory (5.67%, n=9) participants at 28 weeks.
  • Hypomagnesemia has previously been identified in patients taking SRP-5051 and was managed and monitored through prophylactic magnesium supplementation as part of the study protocol.
  • Hypomagnesemia has been seen in earlier clinical studies of SRP-5051 and, throughout MOMENTUM Part B, supplemental magnesium was administered prophylactically.

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Retrieved on: 
Wednesday, December 6, 2023
Quality of life, CYP, Kidney, Risk, Heartburn, Enzyme inhibitor, FDA, TIN, Hypertension, Achlorhydria, Magnesium, Liver, PPI, SJS, Magnesium deficiency, Chest pain, Atazanavir, Endoscopy, Impairment, SCAR, Vitamin B12, Malabsorption, Absorption, PDUFA, CDAD, Calcium, New Drug Application, Gastritis, Enzyme, Food and Drug Administration, Clostridioides, Vonoprazan, Patient, Hip, Hypokalemia, Food, Polyp, GERD, Nelfinavir, Toxicity, EGFR, Wrist, Diarrhea, Hypocalcemia, NDA, Abdominal pain, Urinary tract infection, Hypersensitivity, Stevens–Johnson syndrome, Glomus tumor, Spine, Indigestion, Drug, CGA, Lactation, Pharmaceutical industry

The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

Key Points: 
  • The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
  • “Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life.
  • Symptoms impact overall quality of life and can include episodic heartburn, especially at night, regurgitation, problems swallowing, and chest pain.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
Thursday, October 19, 2023
Cardiac arrest, ECG, Injection, Seizure, Arrhythmia, Nephrocalcinosis, Hypercalcaemia, Infant, Kidney, Continuity, Risk, Hyperkalemia, Death, Parenteral nutrition, Child, Potassium, Lactation, Thrombosis, Acute kidney injury, Milk, Tetany, Toxicity, Phosphate, Patient, Central nervous system, Bolus, Hyperphosphatemia, Hypophosphatemia, Hypotension, Hypocalcemia, Tubing (recreation), Pulmonary embolism, Use, Aluminium, Administration, Late preterm infant, QT, Calcium, Ketoacidosis, Phosphorus, Birth control, Medical device, Pharmaceutical industry, Magnesium deficiency

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

The Role of Magnesium in Mental Health: Simple Solutions for Mental Health Month

Retrieved on: 
Tuesday, May 17, 2022
Mood disorder, Blood, Serotonin, Grammatical mood, Health minister, Lists of diseases, Confusion, Agitation, Memory, Mental, Magnesium, Learning, Depression, Research, Brain, Cerebrospinal fluid, Cognition, Magnesium deficiency, Mental Health Awareness Month, Magnesium chloride, Depression (mood), Reward, Dopamine, GLOBE, Lithium, Salt

FREMONT, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Just in time for Mental Health Awareness month, researchers at Magceutics LLC have extensively studied the brain and the role of magnesium L-threonate in managing mood disorders.

Key Points: 
  • FREMONT, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Just in time for Mental Health Awareness month, researchers at Magceutics LLC have extensively studied the brain and the role of magnesium L-threonate in managing mood disorders.
  • The first report onmagnesium for improving mood was published in 1921, showing success in 220 out of 250 cases .
  • In recent research, only magnesium L-threonate increased brain magnesium levels, even when compared to magnesium citrate, glycinate, gluconate, malate, and chloride .
  • Magnesium L-threonate proved effective for increasing cerebrospinal fluid magnesium levels compared to magnesium chloride or gluconate,resulting in improved cognition in animal models .

The Best Magnesium for Mood, Focus, Stress, Cognition and Other Neurological Issues

Retrieved on: 
Tuesday, April 26, 2022
JAMA, Immunity, Diathesis–stress model, Serotonin, Fear, Government budget balance, Magnesium deficiency, Student, Research, Caffeine, Synapse, Anxiety, Diagnosis, Neuron, Alzheimer's disease, Traffic barrier, Magnesium, Learning, Brain, Dementia, GLOBE, Attention deficit hyperactivity disorder, Patient, Matrix, Growth, Trial of the century, Urine, Even and odd functions, Coffee, Dopamine, Depression, Journal, Animal, Intelligence, MMSE, Lists of diseases, Report, American Medical Association, Anxiety disorder, Mini–Mental State Examination, Phobia, Dietary supplement, ADHD

Many individuals who lead stressful lives may have a higher intake of alcohol, coffee, or caffeine, which increases the elimination of magnesium in the urine.

Key Points: 
  • Many individuals who lead stressful lives may have a higher intake of alcohol, coffee, or caffeine, which increases the elimination of magnesium in the urine.
  • While stress can deplete magnesium, a magnesium deficiency can also enhance a stress response leading to an unhealthy cycle.
  • Interestingly, an animal study in 2004 showed animals receiving diets low in magnesium displayed increased anxiety-related behavior .
  • Importantly, four months after stopping magnesium L-threonate, the MMSE score was still above 24.

OneLavi.com Now offers Health and Wisdom’s Topical Magnesium Product Line

Magnesium deficiency, Oil, Magnesium chloride, Aloe vera, Relaxation, Calcium, PALM, Fatigue, Osteoporosis, Diet, Gel, Inflammation, Skin, GI, Diabetes, Cramp, Beauty, Immune system, GLOBE, Population, Specialization, Salt, Dietary supplement, Aluminium, Explosive

PALM BEACH, FL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- OneLavi.com , a popular boutique health, beauty, and wellness website, now carries Health and Wisdoms topical magnesium products.

Key Points: 
  • PALM BEACH, FL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- OneLavi.com , a popular boutique health, beauty, and wellness website, now carries Health and Wisdoms topical magnesium products.
  • We are excited that One Lavi , a high-quality health and wellness website, offers our premium topical magnesium products to its customers, said Laura Collinwood, President of Health and Wisdom, which sources its raw magnesium chloride oil in the United States.
  • Based in Missouri, Health and Wisdoms topical magnesium products, which contain all-natural minerals and ingredients, include:
    Magnesium Oil USP with Aloe Vera: Purified, full-strength magnesium chloride with organic aloe vera, one of natures finest moisturizers.
  • Magnesium Gel: Less concentrated, Magnesium Gel provides the benefits of purified magnesium chloride formulated with seaweed extract for people with sensitive skin.

Topical Magnesium is the Best Way to Get the Essential Mineral to Keep Your Body in Optimal Condition

Dietary supplement, USP, Sleep, Magnesium, Fatigue, Aloe vera, Inflammation, PALM, Vitamin D, Specialization, Immune system, Joint, Magnesium deficiency, Gel, Magnesium chloride, Risk, Osteoporosis, Relaxation, Magnesium oil, Skin, Cramp, GLOBE, Limestone, Salt, Explosive

Beyond the enjoyment factor, topical application of magnesium is the best way to increase cellular magnesium levels.

Key Points: 
  • Beyond the enjoyment factor, topical application of magnesium is the best way to increase cellular magnesium levels.
  • The best way to get magnesium into your body is with topical application of quality magnesium oils, gels,and bath crystals.
  • Magnesium Gel: Less concentrated, Magnesium Gel provides the benefits of purified magnesium chloride formulated with seaweed extract for people with more sensitive skin.
  • We want them to know that topical magnesium application is the best way to meet theirnecessary magnesium requirements.

The Cardiac Risk of Chloroquine in Unapproved Indications

Retrieved on: 
Friday, March 27, 2020
RTT, Antimalarial medication, QT interval, Branches of biology, Chloroquine, Magnesium deficiency, QTC, Chemistry, Biology, Torsades de pointes, Drug-induced QT prolongation

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.